Preclinical Weight Loss & Synergy Efficacy (AM833 + Semaglutide)

This foundational study evaluated the impact of cagrilintide alone and in combination with a GLP-1 receptor agonist on metabolic markers in rodents.

• Study Objective: To assess the independent and combined effects of the long-acting amylin analog AM833 (cagrilintide) and semaglutide on body weight, food consumption, and body composition (John et al., 2021).

• Methodology: Diet-induced obese (DIO) Sprague-Dawley rats and mice maintained on a high-energy diet were administered daily subcutaneous injections for 24 to 28 days. Testing arms evaluated sub-maximal doses of AM833 monotherapy, semaglutide monotherapy, and two combination protocols (concurrent co-dosing vs. sequential add-on) (John et al., 2021).

• Key Findings (DIO Rats): Monotherapy with $2\ \text{nmol/kg}$ of AM833 resulted in a $-5.8\% \pm 0.9\%$ reduction in baseline body weight. When concurrent co-dosing with semaglutide was introduced, a statistically significant reduction of $-13.1\% \pm 0.7\%$ was recorded, which successfully normalized the body weight metrics of the obese models to match those of lean, age-matched controls (John et al., 2021).

• Key Findings (DIO Mice): While AM833 monotherapy ($10\ \text{nmol/kg}$) showed negligible deviation from baseline ($+1.5\% \pm 2.2\%$), the concurrent combination group achieved a substantial weight reduction of $-9.6\% \pm 1.5\%$. Magnetic resonance scanning confirmed that the recorded weight alterations directly correlated with a reduction in total fat mass rather than lean tissue mass (John et al., 2021).